Skye Bioscience, Inc.
SKYE
$3.29
-$0.26-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.62M | -11.10M | -9.75M | -3.90M | -7.90M |
| Total Depreciation and Amortization | 187.10K | 177.40K | 175.30K | 66.00K | 29.80K |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 111.50K | 250.30K |
| Total Other Non-Cash Items | 1.94M | 2.20M | 2.27M | -2.63M | 2.09M |
| Change in Net Operating Assets | 4.75M | -461.40K | -869.40K | 1.08M | -1.56M |
| Cash from Operations | -10.75M | -9.19M | -8.17M | -5.26M | -7.09M |
| Capital Expenditure | 0.00 | -6.30K | -50.00K | -1.52M | -32.50K |
| Sale of Property, Plant, and Equipment | 89.40K | -- | 140.40K | 72.80K | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -11.94M | -12.80M | -- | -- | -- |
| Cash from Investing | -11.86M | -12.81M | 90.40K | -1.45M | -32.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 6.44M | 0.00 | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -2.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 18.20K | -- | -6.43M | -- | -- |
| Cash from Financing | 18.20K | -- | 5.60K | 0.00 | -2.10M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.58M | -21.99M | -8.08M | -6.71M | -9.22M |